Literature DB >> 21956844

DNA methylation and nonsmall cell lung cancer.

Fang Lu1, Hong-Tao Zhang.   

Abstract

Lung cancer is the leading cause of cancer-related death in men and women worldwide. Owing to the scarcity of effective tools for early detection and therapy strategies, the 5-year survival rate of lung cancer is very poor. Because the accumulation of multiple genetic and/or epigenetic changes, including DNA methylation, has been suggested to contribute to development and progression of human cancers, improved understanding of the relationship between DNA methylation and lung cancer will provide new insights for identifying promising biomarkers for diagnosis, prognosis, and treatment of lung cancer. Here, we present a relatively comprehensive review of DNA methylation and lung cancer, discuss DNA methylation changes in carcinogenesis and metastasis of lung cancer, and explore the association of microRNA with DNA methylation. Additionally, we outline the applications of DNA methylation in clinical practice, such as diagnosis, prognosis, and therapy of lung cancer.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956844     DOI: 10.1002/ar.21471

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  16 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

2.  Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.

Authors:  S Adi Harel; N Bossel Ben-Moshe; Y Aylon; D R Bublik; N Moskovits; G Toperoff; D Azaiza; F Biagoni; G Fuchs; S Wilder; A Hellman; G Blandino; E Domany; M Oren
Journal:  Cell Death Differ       Date:  2015-01-16       Impact factor: 15.828

3.  Prognostic value of Iroquois homeobox 1 methylation in non-small cell lung cancers.

Authors:  Ji Yun Lee; Won Kee Lee; Jae Yong Park; Dong Sun Kim
Journal:  Genes Genomics       Date:  2020-03-21       Impact factor: 1.839

Review 4.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

5.  Promoter Methylation Status Modulate the Expression of Tumor Suppressor (RbL2/p130) Gene in Breast Cancer.

Authors:  Farman Ullah; Taimoor Khan; Nawab Ali; Faraz Arshad Malik; Mahmood Akhtar Kayani; Syed Tahir Abbas Shah; Muhammad Saeed
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

6.  How to get the most from microarray data: advice from reverse genomics.

Authors:  Ivan P Gorlov; Ji-Yeon Yang; Jinyoung Byun; Christopher Logothetis; Olga Y Gorlova; Kim-Anh Do; Christopher Amos
Journal:  BMC Genomics       Date:  2014-03-21       Impact factor: 3.969

Review 7.  The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.

Authors:  Zhang Lou-Qian; Yin Rong; Li Ming; Yang Xin; Jiang Feng; Xu Lin
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

8.  Clinical potential of gene mutations in lung cancer.

Authors:  Miranda B Carper; Pier Paolo Claudio
Journal:  Clin Transl Med       Date:  2015-11-24

9.  ILNCSIM: improved lncRNA functional similarity calculation model.

Authors:  Yu-An Huang; Xing Chen; Zhu-Hong You; De-Shuang Huang; Keith C C Chan
Journal:  Oncotarget       Date:  2016-05-03

10.  The methylation profiles of PRDM promoters in non-small cell lung cancer.

Authors:  Shuang-Xiang Tan; Rui-Cheng Hu; Qian Xia; Yong-Li Tan; Jing-Jing Liu; Gui-Xiang Gan; Li-le Wang
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.